6 articles
CTO-PCI study
CTO-PCI study: percutaneous coronary intervention for chronic total coronary occlusions (blockages of at least 3 months), and the J-CTO, PROGRESS-CTO, CL, and CASTLE scoring systems predicting procedural success and wire-crossing difficulty.
Drug-eluting stent
Drug-eluting stent (DES): coronary stent coated with sirolimus, paclitaxel, everolimus, or similar drugs released to prevent restenosis after angioplasty; first implanted 1999, reduces repeat revascularization versus bare-metal stents but requires dual antiplatelet therapy.
FLOW-DCB trial
FLOW-DCB (NCT07852689) is a planned Korean multicenter randomized noninferiority trial comparing drug-coated balloon-based versus drug-eluting stent-only PCI in 100 adults with de novo coronary lesions, with distal FFR at 6 months as the primary outcome.
Percutaneous coronary intervention
Percutaneous coronary intervention (PCI), or coronary angioplasty, is a catheter-based procedure opening blocked coronary arteries with balloon and stent; introduced by Grüntzig in 1977, drug-eluting stents are its standard, with CABG favored in complex disease.
Reperfusion
Reperfusion is restoration of blood supply to ischemic tissue, mainly via fibrinolysis, primary PCI, or thrombectomy in heart attack and stroke; time-critical, but can itself cause reperfusion injury through oxidative stress, calcium overload, and no-reflow.
Reperfusion therapy
Myocardial reperfusion restores blood flow to ischemic heart muscle, mainly via primary PCI or fibrinolysis for STEMI. Key limits: 90/120-minute targets, reperfusion injury, and no-reflow.